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Abstract
Background: Regulatory T cells (Tregs) can employ a cell contact- and granzyme B-dependent
mechanism to mediate suppression of bystander T and B cells. Murine studies indicate that
granzyme B is involved in the Treg-mediated suppression of anti-tumor immunity in the tumor
microenvironment and in the Treg-mediated maintenance of allograft survival. In spite of its central
importance, a detailed study of granzyme B expression patterns in human Tregs has not been
performed.
Results: Our data demonstrated that natural Tregs freshly isolated from the peripheral blood of
normal adults lacked granzyme B expression. Tregs subjected to prolonged TCR and CD28
triggering, in the presence of IL-2, expressed high levels of granzyme B but CD3 stimulation alone
or IL-2 treatment alone failed to induce granzyme B. Treatment of Tregs with the mammalian target
of rapamycin (mTOR) inhibitor, rapamycin or the PI3 kinase (PI3K) inhibitor LY294002 markedly
suppressed granzyme B expression. However, neither rapamycin, as previously reported by others,
nor LY294002 inhibited Treg proliferation or induced significant cell death in TCR/CD28/IL-2
stimulated cells. The proliferation rate of Tregs was markedly higher than that of CD4+
conventional T cells in the setting of rapamycin treatment. Tregs expanded by CD3/CD28/IL-2
stimulation without rapamycin demonstrated increased in vitro cytotoxic activity compared to
Tregs expanded in the presence of rapamycin in both short term (6 hours) and long term (48
hours) cytotoxicity assays.
Conclusion:  TCR/CD28 mediated activation of the PI3K-mTOR pathway is important for
granyzme B expression but not proliferation in regulatory T cells. These findings may indicate that
suppressive mechanisms other than granzyme B are utilized by rapamycin-expanded Tregs.
Background
Thymus-derived regulatory T cells (Tregs), or natural Tregs
(nTregs), suppress the proliferation of bystander T cells
through CTLA-4, IL-10 or secreted or membrane-bound
forms of TGF-β1 [1]. Granzyme B-mediated suppressive
mechanisms have also been identified and result in the
selective killing of antigen presenting B cells [2] and
bystander effector T cells [3]. In the tumor microenviron-
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ment, granzyme B is important for Treg-mediated sup-
pression of tumor clearance [4]. Recent evidence also
demonstrates a role for Treg-specific granzyme B expres-
sion in the initiation and maintenance of allograft toler-
ance [5]. Thus, granzyme B mediated induction of
apoptosis in target cells represents an additional suppres-
sive mechanism utilized by Tregs. Many of the aforemen-
tioned studies of granzyme B were performed in murine
models utilizing pre-activated Tregs. Preactivation with
sustained T-cell antigen receptor (TCR) and CD28 co-
receptor stimulation in the presence of interleukin-2 (IL-
2) appears to enhance suppressive abilities over those of
freshly isolated nTregs [6]. TCR/CD28/IL-2 stimulation
also results in marked expansion of Tregs and is useful for
the generation of sufficient numbers for adoptive transfer.
Expansion may also influence the expression of granzyme
B, but a detailed study of granzyme B expression patterns
in fresh and expanded human ex vivo nTregs has not been
performed.
IL-2 is essential for the development, maintenance and
function of the regulatory T cell pool. High-level expres-
sion of the IL-2R alpha chain (CD25) is characteristic of
Tregs although it is not specific for them as it is also
expressed on activated effector T cells. Mice deficient in
specific components of the IL-2-IL-2R signaling pathway
suffer from severe autoimmune disease [7] and a lympho-
proliferative syndrome [8,9] and lack functional Tregs
[10]. Triggering of the IL-2R results in the phosphoryla-
tion of STAT5 which binds the promoter region of the
FOXP3 gene suggesting that it has a regulatory function
[11]. Further, T cell specific deletion of STAT5 results in
reduced numbers of Tregs in mice [11]. These studies
demonstrate the importance of IL-2 and the central
dependence on IL-2R mediated STAT5 activation for pro-
motion of FOXP3 expression and acquisition of a sup-
pressive phenotype.
A previous study has shown that IL-2 alone is sufficient to
induce granzyme B and lytic activity in CD8-positive T
cells without TCR stimulation [12]. Natural killer (NK)
cells also upregulate granzyme B in response to IL-2 alone
[13,14] and transcription of granzyme B in primary NK
cells, an NK cell line (NK92) and a T cell line (Jurkat)
requires IL-2 mediated NF-κB activation [14]. Although
phosphoinositide-3-kinase (PI3K) can mediate NF-κB
activation in diverse cell types, neither the PI3K inhibitor
LY294002 nor mitogen activated protein kinase (MAPK)
pathway inhibitors suppress IL-2 stimulated granzyme B
expression in NK92 NK cells [14]. Since Tregs exhibit
some distinct differences in PI3K pathway signaling,
including an altered pattern of AKT activation [4,15,16]
and altered IL-2R signaling [17], there may be differences
in the reliance on pathways upstream of NF-κB for the
induction of granzyme B.
Recent clinical reports suggest that rapamycin, but not
cyclosporine, preserves the peripheral CD4+, CD25+,
FOXP3+ regulatory T cell pool in transplant patients
[18,19]. In vitro, rapamycin preferentially suppresses the
proliferation of mouse CD4+CD25- T cells but not
CD4+CD25bright nTregs under conditions of TCR/CD28
activation in the presence of IL-2 [20,21]. This is likely due
to an inherent lack of dependence, by Tregs, on the mam-
malian target of rapamycin (mTOR) pathway for prolifer-
ation or maintenance of FOXP3 expression levels [20].
Since STAT5 activation is critical for Treg maintenance, the
presence of rapamycin could theoretically enhance IL-2R
mediated activation of the Janus tyrosine kinase (JAK)/
STAT5 pathway thereby favoring Tregs. Therefore,
rapamycin may have both in vivo and in vitro utility for
increasing the relative abundance of Tregs in a physiolog-
ically heterogeneous T cell population. An in vitro study
using human alloreactive conventional CD4+ and CD8+
T cells showed decreased granzyme B expression and
decreased cytotoxic activity in rapamycin treated cells
[22]. However, the effects of rapamycin on granzyme B
expression in human Tregs have not previously been eval-
uated.
In this study we sought to clarify the signaling pathways
in Tregs that are important for granzyme B expression
including the necessity for TCR and CD28 activation. Fur-
thermore, we sought to evaluate the effects of PI3K path-
way inhibitors on granzyme B expression, including the
clinically important mTOR inhibitor rapamycin. We
found that engagement of both the TCR and CD28 was
necessary for granzyme B expression. Inhibitors of the
PI3K-mTOR pathway including both rapamycin and
LY294002 markedly suppressed granzyme B expression
but did not prevent proliferation or interfere with FOXP3
expression levels. In an in vitro cytotoxicity assay using a
Hodgkin lymphoma cell (L428) that we have previously
observed to be susceptible to Treg-mediated killing
(unpublished observation), Tregs expanded in the pres-
ence of rapamycin had a significant decrease in cytotoxic-
ity as compared to Tregs expanded without rapamycin.
The finding that rapamycin suppresses granzyme B expres-
sion may indicate that rapamycin-expanded Tregs utilize
suppressive pathways other than granzyme B to mediate
their effects on bystander lymphocytes under physiologic
conditions.
Methods
Flow cytometry
The following antibodies were used for the flow cytomet-
ric evaluation of T cell subsets in this study: anti-CD4
(clone RPA-T4), anti-CD25 (clone BC96), anti-CD127
(clone HCD127), anti-FOXP3 (clone 259D), all from Bio-
legend Inc. (San Diego, CA). Anti-granzyme B (clone
GB11) was from eBioscience (San Diego, CA). For the car-BMC Immunology 2009, 10:59 http://www.biomedcentral.com/1471-2172/10/59
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boxy-fluorescein diacetate, succinimidyl ester (CFSE)-
based proliferation studies only, anti-FOXP3 (clone
259D/C7) was purchased from BD Biosciences (San Jose,
CA). Cells were permeabilized using a commercially avail-
able fixation and permeabilization kit (FOXP3 fix/perm
kit; Biolegend) per the manufacturer's instructions. Pro-
pidium iodide (PI) and annexin V-PE were from Pharmin-
gen (San Diego, CA). CFSE (Invitrogen, Carlsbad, CA) was
used at a final concentration of 1 μM. Cells were labeled
for 5 minutes in phosphate buffered saline (PBS) contain-
ing CFSE at 37°C then placed in pre-warmed media for 10
minutes, washed two times and plated as indicated in the
figures. Flow cytometry was performed on a FACSCanto II
flow cytometer (BD Biosciences) using FACSDiva soft-
ware (BD Biosciences) except for cell sorting which was
performed on a FACSVantage flow cytometer (BD Bio-
sciences). Final data analysis was performed using FloJo
software (Tree Star, Inc, Ashland, OR). The statistical sig-
nificance of differences in granzyme B expression and
Foxp3 expression between subsets was assessed using the
Student's t-test.
Regulatory T cell isolation/enrichment
Institutional review board (IRB) approval was obtained
from the University of Utah Health Sciences Center to
obtain peripheral blood from normal adult volunteers.
All blood donors provided informed consent prior to
blood collection. Blood was collected by peripheral veni-
puncture in ethylenediaminetetra-acetic acid (EDTA)-
coated vacutainer tubes (BD, Franklin Lakes, NJ). Periph-
eral blood mononuclear cells were isolated from normal
donors by density gradient centrifugation using Ficol-
Paque density medium (GE Healthcare, Uppsala, Swe-
den) according to the manufacturers recommendations.
Subsequently, CD4+, CD25+ Tregs were enriched using a
magnetic bead-based kit (Miltenyi Biotec, Auburn CA)
according to the manufacturers instructions. This tech-
nique routinely resulted in samples that were enriched in
regulatory T cells to a purity of approximately 60-70% or
more based on FOXP3 staining by flow cytometry. How-
ever, higher purity Tregs were required for the cytotoxicity
assays. For the 6-hour cytotoxicity assays, peripheral
blood nTregs were isolated based on flow cytometric sort-
ing of the CD4+, CD25bright (brightest 1/3 of CD25 posi-
tive cells) T cell fraction. For the 48-hour cytotoxicity
assays, isolation based on the CD4+, CD25+, CD127-
dim/negative expression pattern characteristic of Tregs
was performed using a magnetic bead based kit (Miltenyi
Biotec). Both methods resulted in a similar pre-expansion
purity of >90% Tregs, based on flow cytometic evaluation
of FOXP3 expression.
Cell culture, stimulation, expansion and cytotoxicity
Human peripheral blood T cells were maintained in RPMI
1640 medium supplemented with 10% fetal calf serum
(both from Hyclone, Logan, UT) at 37°C in 5% CO2 for
the indicated time. Where indicated, cells were expanded
with anti-CD3/anti-CD28 coated beads (Invitrogen) or
anti-CD3 coated beads (Invitrogen), both at a bead:cell
ratio of 4:1. Where indicated, recombinant human IL-2
(rhIL-2) at 250 IU/mL (R&D Systems, Minneapolis, MN)
was also added. In some experiments, inhibitors were
added to the culture 30 minutes prior to the addition of
the above stimulants. These included rapamycin (Calbio-
chem, San Diego, CA) at 10 ng/mL or 100 ng/mL, or the
PI3K inhibitor LY294002 (Cell Signaling Technology,
Danvers, MA) at 1 μM or10 μM, all in dimethyl sulfoxide
(DMSO; Sigma, St. Louis, MO). In some cases, freshly
enriched CD4+, CD25+ T cell samples were frozen in the
vapor phase of liquid nitrogen in freezing medium (10%
DMSO in RPMI 1640 medium with 20% fetal calf serum)
then thawed and analyzed by flow cytometry at the same
time as their cultured (stimulated) counterparts. These
samples are designated as "unstimulated" in the figures.
Freezing in this way did not have an effect on antigen
expression patterns or viability. The human Hodgkin lym-
phoma cell line, L428 was obtained from the German
Collection of Microorganisms and Cell Cultures (Braun-
schweig, Germany) and maintained in RPMI medium
supplemented with 10% fetal calf serum. For the cytoxoc-
ity assays, purified peripheral blood nTregs were
expanded as indicated then co-cultured at a 3:1 effec-
tor:target ratio with L428 target cells, pre-labeled with
CFSE in media without added stimuli. Controls consisted
of L428 target cells alone or L428 target cells co-cultured
with non-activated conventional CD4+ T cells (Tconv).
An additional positive control for the 6-hour samples con-
sisted of L428 cells alone cultured with 10 μM stau-
rosporine (Sigma) to induce apoptosis. Samples were
then stained with annexin-V-PE to assess early apoptosis
in the 6-hour assays or for propidium iodide to assess late
apoptosis in the 48-hour assays. Annexin-V binding or PI
staining were then assessed in the CFSE labeled target cell
population to quantify apoptosis. Significance was
assessed with the Student's t test.
Results
Granzyme B is not expressed by freshly isolated peripheral 
blood CD4+, CD25+ Tregs or CD4+, CD25- conventional T 
cells from normal adults
Tregs and Tconv were isolated from the peripheral blood
of normal adults. Freshly isolated cells were evaluated for
expression of CD4, CD25, FOXP3 and granzyme B by
flow cytometry. FOXP3 expression was only seen in the
CD25+ subset. Granzyme B expression was not detected
in peripheral blood CD4+ T cells in any of the freshly iso-
lated samples from the four normal volunteers tested.
Representative dot plots showing expression of the above
markers are shown in Figure 1 for the fraction depleted of
Tregs (Figure 1A) and the fraction enriched in Tregs (Fig-BMC Immunology 2009, 10:59 http://www.biomedcentral.com/1471-2172/10/59
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ure 1B).
Expansion of ex vivo enriched human Tregs with CD3/
CD28 stimulation and IL-2 induces expression of granzyme 
B but IL-2 alone or CD3 stimulation alone does not
Tregs were enriched from peripheral blood then subjected
to stimulation for 4 days in vitro using IL-2 alone (250 IU/
mL), CD3 stimulation alone with anti-CD3 coated beads
or combined CD3/CD28 stimulation with anti-CD3 and
anti-CD28 coated beads with IL-2 (250 IU/mL). On day 4,
samples were simultaneously stained for CD4, FOXP3
and granzyme B (or an equal concentration of isotype
control antibody instead of anti-granzyme B) and evalu-
ated by flow cytometry (Figure 2). Granzyme B was
assessed in the distinct FOXP3 bright population repre-
senting Tregs (gate shown) and granzyme B staining was
expressed as mean fluorescence intensity (MFI) (Figure 2).
Neither IL-2 alone or anti-CD3 alone promoted an
increase in granzyme B expression. However, anti-CD3/
anti-CD28 coated beads plus IL-2 induced a marked
increase in the level of granzyme B staining. Staining of a
duplicate CD3/CD28 and IL-2 stimulated sample with
anti-CD4, anti-FOXP3 and a granzyme B isotype control
antibody confirms the specificity of anti-granzyme B anti-
body staining (Figure 2).
Inhibition of mTOR by rapamycin and inhibition of PI3K by 
LY294002 suppresses granzyme B expression in TCR/
CD28/IL-2 stimulated Tregs
Enriched peripheral blood nTregs were subjected to in
vitro expansion for 4 days using CD3/CD28 beads and IL-
2 (250 IU/mL) in the presence of the indicated inhibitor.
CD4, CD25, granzyme B and FOXP3 expression patterns in freshly isolated Treg-depleted peripheral blood CD4+, CD25-  conventional T cells (panel A) and enriched CD4+, CD25+ natural regulatory T cells (panel B) Figure 1
CD4, CD25, granzyme B and FOXP3 expression patterns in freshly isolated Treg-depleted peripheral blood 
CD4+, CD25- conventional T cells (panel A) and enriched CD4+, CD25+ natural regulatory T cells (panel B). 
Utilizing a CD4/CD25 magnetic bead-based technique, the enriched samples of nTregs were routinely comprised of 60-70% 
Tregs based on FOXP3 expression. This data is representative of that seen in multiple subsequent experiments utilizing 
enriched Tregs. Similar results were obtained in 4 normal donors.
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In the case of rapamycin, similar conditions have previ-
ously been shown to lead to selective expansion of CD4+,
CD25bright, FOXP3+ Tregs with retained suppressive capa-
bilities [21]. Using flow cytometric evaluation of CD4,
FOXP3 and granzyme B and gating on FOXP3-bright cells
(Figure 3A), we found that PI3K inhibition resulted in a
dose-dependent suppression of granzyme B expression
that was complete at 10 μM LY294002 (Figure 3B).
Rapamycin treatment at only 10 ng/mL also resulted in
marked suppression of granzyme B expression (Figure
3B). To confirm that these findings were not simply due
to the induction of cell death by the inhibitors, the cul-
Granzyme B expression patterns by flow cytometry in enriched Tregs freshly isolated (unstimulated) or Tregs treated with IL- 2 (250 IU/mL) or anti-CD3 coated beads (4:1 ratio of beads to cells) or anti-CD3/anti-CD28 coated beads (4:1 ratio of beads  to cells) plus IL-2 (250 IU/ml) for 4 days Figure 2
Granzyme B expression patterns by flow cytometry in enriched Tregs freshly isolated (unstimulated) or Tregs 
treated with IL-2 (250 IU/mL) or anti-CD3 coated beads (4:1 ratio of beads to cells) or anti-CD3/anti-CD28 
coated beads (4:1 ratio of beads to cells) plus IL-2 (250 IU/ml) for 4 days. Granzyme B expression in the FOXP3+ 
gated Treg population at left (labeled Tr) is shown in histogram form at right (top right). For ease of comparison, the bottom 
right plot shows the level of staining of CD3/CD28/IL-2 stimulated cells with a granzyme B isotype control antibody. The data 
is representative of more than three experiments using multiple donors.
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tures were evaluated for PI staining by flow cytometry
(Figure 3C). There was no increase in the number of PI
positive cells in any of the inhibitor treated samples as
compared to samples without inhibitor treatment. Flow
cytometric evaluation of FOXP3-bright cells demon-
strated an activation induced increase in the level of
FOXP3 expression (Figure 3A and 3D), versus that seen in
freshly isolated peripheral blood Tregs in all stimulated
samples, regardless of inhibitor. Evaluation of triplicate
samples showed no significant suppression (or augmenta-
tion) of activation-induced enhancement of FOXP3
expression in the rapamycin or low dose LY294002
treated samples (Figure 3D). The sample treated with high
dose LY294002 (10 μM) showed a slight but significant
decrease in activation induced FOXP3 enhancement (Fig-
ure 3D). Given this finding, we conclude that there is no
Granzyme B expression in Tregs analyzed by flow cytometric gating on FOXP3-bright cells (panel A, population labeled Tr)  without stimulation or with stimulation by CD3/CD28 beads and IL-2 for 4 days without inhibitors (labeled no inhibitor) or  with rapamycin (10 ng/mL) or the PI3K inhibitor LY294002 (1 or 10 μM) Figure 3
Granzyme B expression in Tregs analyzed by flow cytometric gating on FOXP3-bright cells (panel A, popula-
tion labeled Tr) without stimulation or with stimulation by CD3/CD28 beads and IL-2 for 4 days without inhib-
itors (labeled no inhibitor) or with rapamycin (10 ng/mL) or the PI3K inhibitor LY294002 (1 or 10 μM). The data 
is graphed as mean of the mean fluorescence intensities (MFI) of granzyme B staining in the FOXP3-bright population in tripli-
cate samples (panel B). Statistical comparison of the indicated data sets using a t-test is shown (** denotes P < .003). In order 
to confirm that the decrease in granzyme B expression was not attributable to induction of cell death in the rapamycin or 
LY294002-treated cells, samples were stained with propidium iodide (PI) (panel C). To facilitate interpretation, we next com-
pared FOXP3 MFIs in the samples. The level of FOXP3 expression in the gated FOXP3-bright population (see panel A) in one 
unstimulated sample of Tregs (panel D, far left) and in triplicate stimulated samples treated with inhibitors as indicated is shown 
as a bar graph (panel D). Pairwise statistical comparisons are shown (NS-not significant with P > .05; * denotes P = .02). This 
data is representative of more than three experiments from multiple donors.
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correlation between granzyme B expression and FOXP3
expression.
CD4+, FOXP3+, CD127 negative Tregs expand 
preferentially in the setting of rapamycin treatment when 
compared with CD4+, FOXP3-, CD127+ Tconv
The proliferation of Tregs and Tconv in response to the
strong stimuli of CD3/CD28 beads and IL-2 was assessed
in the presence of mTOR or PI3K inhibitors. Enriched
peripheral blood Tregs (approximately 80% Tregs, 20%
Tconv), pre-labeled with CFSE, were cultured with
rapamycin (10 and 100 ng/mL) or LY294002 (1 μM) plus
CD3/CD28 beads and IL-2 (250 IU/mL) for 4 days. To
quantify the initial number of Tregs and Tconv in the cul-
ture, CD4, FOXP3 and CD127 levels were assessed by flow
cytometry prior to expansion (Figure 4A). After expan-
sion, single cell evaluation of CFSE staining and FOXP3
expression was performed by flow cytometry in order to
separately quantify proliferation in the FOXP3+ and
FOXP3- subsets. This revealed preferential expansion of
Tregs in the presence of rapamycin at 10 ng/mL and 100
ng/mL but similar proliferation in the sample expanded
without inhibitors and in the sample expanded in the
presence of LY294002 (Figure 4B). To more rigorously
Treg-enriched peripheral blood CD4+ T cells containing approximately 80% Tregs (Tr) and 20% Tconv (Tc) were evaluated  for expression of CD4, FOXP3 and CD127 prior to expansion (panel A) Figure 4
Treg-enriched peripheral blood CD4+ T cells containing approximately 80% Tregs (Tr) and 20% Tconv (Tc) 
were evaluated for expression of CD4, FOXP3 and CD127 prior to expansion (panel A). Samples were next 
labeled with CFSE then expanded for six days with CD3/CD28 beads and IL-2. Subsequently, samples were simultaneously 
evaluated for FOXP3 expression and CFSE staining intensity by flow cytometry. Dot plots showing proliferation in the 
FOXP3+ and FOXP3- fractions are shown in panel B along with an overlay of histograms for CFSE staining (Tregs are shown in 
red and Tconv are shown in blue). As a control a CFSE-labeled but unstimulated sample is shown in black. The data is repre-
sentative of three similar experiments from multiple donors.
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compare the proliferative response of the FOXP3+ and
FOXP3- fractions in the context of mTOR inhibition by
rapamycin the percentage of cells in each generation was
quantified (Table 1). In the setting of 10 ng/mL rapamy-
cin, which corresponds to therapeutic human plasma lev-
els [23], six total Treg generations and five Tconv
generations could be defined by CFSE staining with
42.3% of Tregs in generations 5 and 6 versus 10.4% of
Tconv. In the samples subjected to the highest rapamyin
concentration (100 ng/mL) similar results were obtained
although there was suppression of proliferation in both
Treg and Tconv fractions (22% of Tregs in generations 4
and 5 vs 6.7% of Tconv). These findings show that under
identical conditions, proliferation of Tregs is highly
favored by rapamycin treatment.
Expansion of CD4+, FOXP3+, CD127- Tregs results in 
upregulation of the IL-7R to levels equivalent to those seen 
in FOXP3- Tconv
The IL-7 receptor (CD127) has been shown to be
expressed at lower levels in Foxp3+ Tregs and to inversely
correlate with their suppressive capacity [24]. In agree-
ment, we found that prior to expansion, CD127 levels
were indeed lower in FOXP3+ Tregs (Figure 4A/Figure 5).
We wondered whether expansion with CD3/CD28 stimu-
lation and IL-2 resulted in a retained pattern of low
CD127 expression in Tregs. Interestingly, we found essen-
tially identical CD127 levels in expanded Tregs and Tconv
(Figure 5) suggesting a limited utility for CD127-based
purification techniques for separating in vitro expanded
Tregs from Tconv.
Tregs expanded in vitro without rapamycin have increased 
in vitro cytotoxicity versus Tregs expanded in rapamycin
Multiple previous studies have demonstrated that Tregs
expanded in rapamycin maintain their suppressive func-
tion [20,21,25]. However, such assays require co-culture
of Tregs with target cells, usually CD4+ or CD8+ conven-
tional T cells, in the presence of TCR/CD28 stimulation
either via antibodies or irradiated antigen presenting cells,
the very conditions that we have shown to induce
granzyme B expression. In order to avoid inducing de novo
granzyme B expression during suppression assays in Tregs
previously expanded in rapamycin, and to separate the
suppressive and cytotoxic function of Tregs, we developed
a flow cytometry based cytotoxicity assay using a Hodgkin
lymphoma cell line (L428) that we had previously
observed to be susceptible to in vitro Treg-mediated cyto-
toxicity (unpublished observation). We used this observa-
tion to test the cytotoxic function of Tregs expanded in
vitro  with and without rapamycin. Peripheral blood
nTregs were isolated by flow cytometry based on CD4+/
CD25bright characteristics (brightest 1/3 of CD25+ cells;
Figure 6A/B) or by a bead-based method designed to iso-
late based on a CD4+, CD25+, CD127- surface antigen
expression profile (Figure 6C/D). Both methods gave sim-
ilar pre-expansion nTreg purities of >90%, based on
FOXP3 expression. nTregs were then expanded with CD3/
CD28 beads plus IL-2, with and without rapamycin (10
ng/mL) as indicated. Post-expansion Treg purities are
shown in Figure 6A/C. Samples were subsequently co-cul-
tured at a 3:1 ratio of FOXP3+ Tregs (or Treg-depleted
nonactivated Tconv as a control) to CFSE-labeled L428
target cells for 6 or 48 hours as indicated. Apoptosis was
measured by flow cytometric analysis of the CFSE labeled
target cell fraction. Early apoptosis was measured by
Table 1: Percent cells in each generation, based on CFSE staining, for the rapamycin treated samples shown in Figure 4B.
Generation CD3/CD28/IL2+10 ng/ml rapamycin CD3/CD28/IL2+100 ng/ml rapamycin
FOXP3- (%) FOXP3+ (%) FOXP3- (%) FOXP3+ (%)
0 7.9 3.9 22.1 23.8
1 9.7 5.4 17 8.3
2 17.5 8.4 28.1 17
3 28.9 14.6 26.1 28.9
4 25.6 25.4 6.7 19.2
5 10.4 28.4 - - - 2.8
6 - - - 13.9 - - - - - -
Total 100 100 100 100BMC Immunology 2009, 10:59 http://www.biomedcentral.com/1471-2172/10/59
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annexin-V binding to target cells in the 6 hour cytotoxicity
assays. For the 48-hour assays, late apoptosis was meas-
ured by PI staining of the target cell population. Repre-
sentative dot plots from a 6-hour cytotoxicity assay are
shown in Figures 6A/B. Statistical analysis of multiple 6-
hour replicates showed a significant increase in annexin-
V-positive apoptotic target cells co-cultured with nTregs
expanded without rapamycin (versus target cells cultured
alone; P = .04). The increase in apoptotic target cells co-
cultured with nTregs expanded in rapamycin was not sta-
tistically significant (P = .07). Staurosporine treated cells
served as a positive apoptosis control. For the 48-hour
cytotoxicity assays, representative data, including statisti-
cal significance, are shown in Figure 6C/D. Although cyto-
toxicity was present for both Treg subsets (+/- rapamycin),
it was significantly higher for Tregs expanded without
rapamycin. Thus, in this system cytotoxicity at both 6 and
48 hours correlates with granzyme B expression, and
inversely with rapamycin exposure, in expanded nTregs.
Discussion
Adoptive transfer of in vitro expanded, ex vivo peripheral
blood nTregs has been suggested as a potential treatment
for patients suffering from autoimmune disorders,
chronic inflammatory diseases, graft-versus-host disease
(GVHD) or to suppress organ rejection in transplant
patients [26-28]. Indeed, early animal studies in the set-
ting of solid organ transplantation have been promising
[27,29-31]. However, the optimum conditions for gener-
ating or expanding suppressive regulatory T cells remains
somewhat controversial. For the generation of suppres-
sive, induced Tregs (iTregs) from CD4+, CD25- naïve
Tconv, TGF-β1 is required [32,33] as is IL-2 [34]. For pol-
yclonal expansion of peripheral blood nTregs, sustained
T-cell receptor activation and CD28 co-receptor triggering
using plate- or bead-bound anti-CD3 and anti-CD28
along with high dose IL-2 is necessary [6,35]. Interest-
ingly, expansion of polyclonal nTregs with anti-CD3/anti-
CD28 stimulation and IL-2 elevates their suppressive
capabilities above those of freshly isolated nTregs in an in
CD4+ peripheral blood T cells, enriched for Tregs but containing a population of Tconv, were evaluated by flow cytometry for  CD127 and FOXP3 prior to expansion and after 4 days of expansion with CD3/CD28 beads and IL-2 Figure 5
CD4+ peripheral blood T cells, enriched for Tregs but containing a population of Tconv, were evaluated by 
flow cytometry for CD127 and FOXP3 prior to expansion and after 4 days of expansion with CD3/CD28 beads 
and IL-2. A comparison of the level of CD127 staining is shown in the histograms (Tr = Tregs, Tc = Tconv). The data is rep-
resentative of multiple experiments using different donors.
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vivo  murine model[6]. Thus, in vitro expansion may
impart properties that are absent in freshly isolated
nTregs. However, the mechanisms that account for this
are unclear.
Tregs have an altered pattern of PI3K-mediated TCR and
IL-2R signaling and, related to this, they have a unique
ability to expand in the presence of rapamycin. However,
other potentially unique aspects of TCR- or IL-2-mediated
Treg signaling have not been thoroughly explored. Our
Fresh peripheral blood nTregs were purified based on flow cytometric sorting of the CD4+, CD25-bright T cell subset (bright- est 1/3 of CD25+ cells; Figure 6A/B) or by a bead based method based on a CD4+, CD25+, CD127- surface antigen expres- sion profile (Figure C/D) then expanded for four days with CD3/CD28 beads and IL-2 with and without 10 ng/mL rapamycin Figure 6
Fresh peripheral blood nTregs were purified based on flow cytometric sorting of the CD4+, CD25-bright T cell 
subset (brightest 1/3 of CD25+ cells; Figure 6A/B) or by a bead based method based on a CD4+, CD25+, 
CD127- surface antigen expression profile (Figure C/D) then expanded for four days with CD3/CD28 beads and 
IL-2 with and without 10 ng/mL rapamycin. Both isolation methods gave similar results. CD4 and FOXP3 expression 
were then evaluated on day 4 and showed relative purity of the resulting Treg populations (90.8% and 90.5% in panel A and 
85% and 83% as indicated in panel C). Tregs were then co-cultured at a 3:1 ratio of Tregs (Tr = Tregs expanded without 
rapamycin; TrRapa = Tregs expanded with rapamycin) to CFSE labeled L428 target cells. Samples were plated in triplicate in 
media without additional stimuli or inhibitors. After 6 or 48 hours as indicated, apoptosis was assessed in the CFSE labeled 
L428 target cell population by flow cytometric evaluation of annexin-V binding (early apoptotic cells) or propidium iodide (PI) 
staining (late apoptotic cells) in the 6 and 48-hour assays, respectively (panels B and D). Control samples consisted of CFSE-
labeled L428 cells alone, L428 cells alone exposed to 10 μM staurosporine (6 hour cytotoxicity assays only) and nonactivated 
Treg-depleted T cells (Tc) plated at a 3:1 ratio with labeled L428 target cells. Representative dot plots for a 6-hour cytotoxicity 
assay, with annexin-V positive apoptotic target cells highlighted with percentages, are shown in panel B. Replicates from a 48-
hour cytotoxicity assays are graphed in panel D. Statistical comparison of the indicated data sets was performed using a t-test 
(NS-not significant with P > .05, * denotes P < .02, ** denotes P = .003). The data shown in both of the timepoints are repre-
sentative of three experiments using multiple donors.
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goal was to evaluate granzyme B expression patterns in in
vitro expanded ex vivo human peripheral blood nTregs and
determine the signals that induce granzyme B. Further-
more, we studied the necessity for PI3K-mTOR signaling
for granzyme B expression and the effects of rapamycin.
We found that granzyme B was not expressed in any
peripheral blood CD4+ T cell subset in the normal donors
tested. Utilizing enriched samples of peripheral blood ex
vivo nTregs typically containing approximately 70% Tregs
and 30% Tconv by FOXP3 expression, we found that T cell
receptor triggering alone was insufficient to induce
granzyme B expression, consistent with previous reports
that Tregs are anergic in vitro to TCR stimulation alone
[36]. Similarly, high dose IL-2 (250 IU/mL) treatment
alone failed to induce granzyme B expression. This obser-
vation is in contrast to previously reported findings in NK
cells and CD8+ T cells where IL-2 without additional stim-
uli results in elevated expression of granzyme B [12,13].
We found that sustained activation of both the TCR and
CD28 along with high dose IL-2, conditions optimal for
Treg expansion [35], led to a rapid and marked induction
of granzyme B. However, pretreatment of CD3/CD28/IL-
2 expanded Tregs with rapamycin or the PI3K inhibitor
LY294002 resulted in a marked suppression of granzyme
B. Thus, signaling through the PI3K-mTOR pathway
appears necessary to support granzyme B expression. The
observation that IL-2 treatment alone fails to induce
granzyme B expression may be related to the fact that
Tregs, in contrast to effector T cells, do not activate down-
stream targets of PI3K in response to IL-2R stimulation
[17] apparently due to inhibition by PTEN [37]. Thus, in
addition to the lack of proliferation in response to IL-2
previously shown by others [17], the lack of granzyme B
induction by IL-2 outlined here is an additional physio-
logic ramification of the altered IL-2R signaling in Tregs
that has not previously been reported.
We, like other groups [38], found that rapamycin-treated
Tregs subjected to strong CD3/CD28 stimulation in the
presence of IL-2 retain their ability to proliferate. Single
cell flow cytometric analysis of proliferation of Tregs and
Tconv under identical expansion conditions revealed a
striking difference in proliferative capacity in the setting of
rapamycin treatment that appears to markedly favor
Tregs. This effect was most evident at a concentration of
10 ng/mL, a dose that corresponds to therapeutic human
plasma levels [23]. Higher rapamycin doses yielded sup-
pression of both Treg and Tconv, although to a greater
degree in the latter. We have also shown that the activa-
tion induced enhancement in FOXP3 protein levels in
stimulated cells is similar, regardless of the presence of
rapamycin or low dose PI3K inhibition. We therefore con-
clude that granzyme B is not simply a so-called "activation
marker" but that it is subject to a distinct means of regula-
tion that depends on a TCR/CD28 induced PI3K-mTOR
mediated signaling mechanism that is distinct from those
mechanisms that regulate proliferation and FOXP3
expression. Of note, many of the previous studies of the
role of granzyme B in regulatory T cells have been per-
formed in murine model systems [2-5] and studies of
granzyme B in human Tregs are relatively few. Previous
studies by Grossman, et al. utilizing human cells described
expression of granzyme B in adaptive (induced) regula-
tory T cells generated in vitro by anti-CD3/anti-CD46
treatment in the presence of IL-2 that resulted in cytotoxic
activity against human target cell lines [39,40]. This same
group found much lower levels of granzyme B expression
in CD3/CD28/IL-2 expanded natural Tregs [39]. The rea-
son for this difference is unclear but may be related to dif-
ferences in expansion conditions and strength of stimuli
between this, and the current study.
We have also shown that longer term (4 days) activation
results in upregulation of surface IL-7R (CD127) levels in
nTregs but not in Tconv. This has the effect of equalizing
post-activation CD127 expression in both T cell types.
This finding indicates that using low-level CD127 expres-
sion to identify or sort nTregs may be problematic in the
setting of CD3/CD28/IL-2 activated or expanded Tregs.
Induction of Foxp3 expression in Tregs differentiated in
vitro from naïve CD4+, FOXP3- T cells treated with TGFβ
is blocked by transfection with constitutively active forms
of AKT [16]. However, nTregs exhibit little suppression of
pre-existing FOXP3 protein levels when treated in a simi-
lar fashion [16]. Taken together, the previous data and
that presented here indicate that PI3K-AKT-mTOR signal-
ing is dispensible for nTreg proliferation, it appears to
suppress de novo induction of FOXP3 expression in naïve
T cells, it has little impact on pre-existing FOXP3 protein
levels or in the activation induced increase in FOXP3 seen
in activated nTregs, and it promotes a granzyme B-medi-
ated cytotoxic function in activated nTregs. Thus, mTOR
signaling may yet have a role in Treg physiology.
Conclusion
In human cells, we confirm the finding that rapamycin
treatment favors the outgrowth of nTregs in response to
strong stimuli due to differential inhibition of CD4+,
CD25- conventional T cells under identical expansion
conditions. Furthermore, our data shows that PI3K-mTOR
signaling is important for CD3/CD28 induced granzyme
B expression in human nTregs. Tregs expanded in rapamy-
cin exhibit suppressed granzyme B expression and a corre-
spondingly lower cytotoxic activity in an in vitro
cytotoxicity assay using a cell line as target cells. The
effects of rapamycin on granzyme B expression may sug-
gest that other suppressive strategies are dominant in
rapamycin treated Tregs under physiologic conditions.BMC Immunology 2009, 10:59 http://www.biomedcentral.com/1471-2172/10/59
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